Menu
Search
|

Menu

Close
X

Cocrystal Pharma Inc COCP.OQ (NASDAQ Stock Exchange Capital Market)

4.38 USD
-- (--)
As of Jul 13
chart
Previous Close 4.38
Open --
Volume --
3m Avg Volume --
Today’s High --
Today’s Low --
52 Week High 6.43
52 Week Low 1.61
Shares Outstanding (mil) 29.70
Market Capitalization (mil) 130.08
Forward P/E 312.63
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.064
FY17
-0.029
FY16
-3.152
FY15
-2.584
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
312.63
33.20
Price to Sales (TTM)
vs sector
--
8.07
Price to Book (MRQ)
vs sector
1.03
4.28
Price to Cash Flow (TTM)
vs sector
275.59
22.38
Total Debt to Equity (MRQ)
vs sector
1.96
17.39
LT Debt to Equity (MRQ)
vs sector
1.96
13.21
Return on Investment (TTM)
vs sector
0.32
13.23
Return on Equity (TTM)
vs sector
0.37
15.28

EXECUTIVE LEADERSHIP

Raymond Schinazi
Chairman of the Board, Since 2015
Salary: --
Bonus: --
Sam Lee
President, Since 2014
Salary: $203,620.00
Bonus: --
Gary Wilcox
Interim Chief Executive Officer, Vice Chairman of the Board, Since 2015
Salary: $133,487.00
Bonus: --
James Martin
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
David Block
Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1860 Montreal Rd
TUCKER   GA   30084-5709

Phone: +1425.3987178

Cocrystal Pharma, Inc., is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.

SPONSORED STORIES